Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with…
The $2 Trillion Valuation Debate Skips What Anthropic Knows
Pharmacore secures funding to improve medication regimen reviews in long-term care